🔥 Don’t Miss the Elympics IDO on SeaFi – Launching July 22 🔥@elympics_ai is building the next-gen infrastructure for viral Play2Win games integrated directly into superapps and social platforms.Backed by some of the most iconic names in web3 and gaming:Pudgy Penguins, Doodles, Flappy Bird, Crypto Banter – and more.IDO Timeline:Snapshot Date: July 21 (UTC)IDO Start: July 22 (UTC)IDO Close: July 23 (UTC)Key Details:Token: $ELPChain: EthereumSoft Cap: $500,000Hard Cap: $1,000,000IDO Price: $0.01857Vesting: 40% ...

Key Takeaways AstraZeneca's anselamimab missed the primary endpoint in both phase III CARES studies for AL amyloidosis. The drug showed a clinically meaningful benefit in a prespecified subgroup, but details remain undisclosed. AZN plans a full analysis of the data and will present findings at an upcoming medical meeting.AstraZeneca (AZN) reported disappointing results from two late-stage studies that evaluated its investigational light chain depleter antibody, anselamimab, in certain patients with a rare ...

Peace between Armenia and Azerbaijan could lead to Armenia being integrated into the region’s “middle corridor” for trade and energy that links China and Central Asia to Europe, bypassing Russia.The effects of this would be felt widely https://t.co/mdyy9wSBU9 ...

Symptoms include a flagging libido, tiredness, shrinking muscles and growing body fat https://t.co/2R90DWIrZT ...

平台币HEST已经完成了三轮的IDO，总量93000K个。第一轮的价格是0.015usdt，第二轮的价格是0.018usdt，第三轮的价格是0.0215usdt。7.5进行的超额认购，目标额度是100,000 USDT，超募了20倍。北京时间7.9 20:00进行TGE，开盘时流通占供应量的0.3%。 ...

O que mata mais do que o cigarro é mais perigoso do que o colesterol alterado e ameaça nossa longevidade, nossa expectativa de vida, mais do que a nossa pressão arterial descontrolada. A resposta para essa pergunta pode surpreender vocês, é a solidão. Bem-vindos à ciência revolucionária da longevidade relacional, que mostra que a conexão humana é muito mais do que um prazer da vida ou boa companhia.É uma necessidade vital. Tem um ditado que vocês devem conhecer que diz que sozinhos nós vamos mais rápido, ma ...

[Música] [Música] Madre mía, cuánta gente. E pues nada, ya lo han dicho todo. No somos margarina, no somos manteca. Está más buena. Va para dulce, va para salado, va para Jerez. Entonces, os vamos a hacer cantar. Lo siento, [Música] [Aplausos] mané. Mani, mani, mani. ¿Qué preferís? Aco no hay que ser perezosos. Venga, un, dos, tres y [Música] pa. [Música] Y ahora os vais a tener que copiar. [Música] ¿Cómo? Si te quieres por el pico divertir, cómete un cucuruchito de maní. [Música] Qué calentito y rico está. ...

[Música] Hay que decir, buenas tardes, eh, a todo el mundo. Hay que decir, lo hemos comentado antes, pero quiero volver a insistir en ello, en que esto es un evento sin ánimo de lucro y nuestros ponentes vienen por el puro placer de compartir este ratito con vosotros. ¿Cómo que no sin ánimo de lucro.Aunque aunque sé que lo dice de broma, a mí me da un microinfarto. No, pero es que cree que es de broma. ¿Dónde está mi manager.Eres tonto. Venga, tira. Bueno, como hemos hablado, vamos a ir lanzando preguntas, ...

Core Insights - The UK has granted marketing authorization for acoramidis, branded as BEYONTTRA, for treating wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) [1][2] - Acoramidis is the first and only approved treatment for ATTR-CM in the U.S., EU, UK, and Japan, with a label specifying near-complete stabilization (≥90%) of transthyretin (TTR) [1][3] - The approval is based on positive results from the Phase 3 ATTRibute-CM study, which demonstrated significant cardiovascular benefits [2][3] Summary by Category Product Approval - The Medicines and Healthcare products Regulatory Agency in the UK has approved acoramidis for ATTR-CM treatment [1][2] - Acoramidis has previously received approvals in the U.S. as Attruby™ and in the EU and Japan as BEYONTTRA [3] Clinical Study Results - The ATTRibute-CM study involved 632 participants and showed a 42% reduction in composite all-cause mortality and recurrent cardiovascular-related hospitalization events at Month 30 compared to placebo [1][2] - A 50% reduction in the cumulative frequency of cardiovascular-related hospitalization events was also observed at Month 30 [1] Market and Financial Aspects - BridgeBio will receive royalties in a tiered structure starting in the low-thirties percent on sales of BEYONTTRA in the UK [1][4][5] - Bayer is responsible for all commercial activities related to acoramidis in the UK [1][3]